GLP1R and metabolic dysfunction-associated steatohepatitis: The SYNERGY-NASH trial, for example, demonstrated that tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, led to the resolution of MASH and weight reduction in patients with T2DM [91].